Sleep Disorders

At SLEEP 2026, the section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed the high burden of undiagnosed sleep apnea in hospitalized patients. [WATCH TIME: 5 minutes]

Data from phase 3 studies presented at SLEEP 2026 showed that investigational oveporexton was associated with improvements in REM sleep architecture and sleep-related symptoms in patients with NT1.

Here's some of what is coming soon to NeurologyLive® this week.

Romy Hoque, MD, Professor of Neurology at Emory University, previews the 2026 SLEEP Annual Meeting, highlighting key themes across neurodegeneration, hypersomnolence, sleep apnea, and the growing role of GLP-1 receptor agonists in sleep medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Todd Arnedt, PhD. [LISTEN TIME: 18 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 22, 2026.

The professor of psychiatry at the UCLA discussed postmortem findings suggesting that locus coeruleus neuron loss may be a more consistent feature of narcolepsy than hypocretin deficiency.

New findings suggest that patients with obstructive sleep apnea and excessive daytime sleepiness exhibit distinct endotypic traits that may influence disease severity and symptom expression.

Two newly published studies highlighted both the phase 3 efficacy data and biologic rationale supporting AD109 as a potential oral treatment option for obstructive sleep apnea.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

Catch up on any of the neurology headlines you may have missed in April 2026, compiled into 1 place by the NeurologyLive® team.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

A phase 1b/2 trial presented at AAN 2026 showed HS-10506, a selective OX2R antagonist, significantly improved sleep latency and overall sleep outcomes in adults with insomnia.

Data from the phase 2 Vibrance-1 trial showed that alixorexton was associated with improvements in patient-reported outcomes in adults with narcolepsy type 1 over up to 12 to 13 weeks of follow-up.

An exploratory analysis of a phase 3 trial showed that solriamfetol improved daytime wakefulness without producing consistent or clinically meaningful changes in nocturnal sleep quality measures.

A recent population-based data analysis of Korean adults reported those with anxiety and certain sleep disturbances experienced longer durations of morning grogginess, known as sleep inertia.

Neurology News Network for the week ending April 11, 2026. [WATCH TIME: 4 minutes]

A meta-analysis of randomized trials confirmed modafinil improves both objective and subjective measures of daytime sleepiness in narcolepsy.

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.